Cell therapy includes various types of cell-based therapies and therapies that manipulate the bioactive potential of cells. Cell therapy uses live whole cells or their components to treat diseases such as cancer, autoimmune disorders, and neurological disorders. Cell-based therapy involves replacing or repairing damaged or defective cells with normal healthy cells. Various types of cell-based therapies include hematopoietic stem cell transplantation (HSCT), mesenchymal stem cell (MSC) therapy, chondrocyte transplant, and dendritic cell therapy. The global cell therapy market witnesses a surge in R&D activities and clinical trials to develop therapies for various indications. Additionally, advancements in technologies for cell handling and processing have enabled researchers to overcome challenges in the fabrication of cell-based therapeutics.
The global cell therapy market is estimated to be valued at US$ 16.4 billion in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Increasing Research and Development Activities (as mentioned in the heading) is a key driver propelling the growth of the cell therapy market. There is a substantial increase in investments by biotechnology and pharmaceutical companies to develop cell-based therapies. For instance, according to the Alliance for Regenerative Medicine, total global investment in cell therapies reached US$ 1.5 billion in 2020. Additionally, various clinical trials are being conducted to evaluate the safety and efficacy of cell therapies in treating various indications. For instance, in October 2020, FUJIFILM Cellular Dynamics, Inc. initiated a Phase 1/2a clinical trial to evaluate safety and efficacy of human induced pluripotent stem cell (iPSC)-derived retinal pigment epithelial (RPE) cells for the treatment of dry age-related macular degeneration (AMD). The second driver is the advancements in cell processing technologies which have enabled efficient isolation, cultivation, and delivery of viable cells. Novel technologies allow precise quality checks and have automated several workflow steps involved in cell processing, thus enhancing process efficiency.
The global cell therapy market is dominated by the allogenic sub segment. Allogenic therapies utilize donor cells from other individuals and this allows the development a treatment than can be applied to broad range of patients rather than developing individualized therapies. This provides significant advantages in terms of costs and time required for development. The allogenic sub segment currently holds around 75% share of the total cell therapy market owing to these advantages.
Political: The cell therapy market is highly regulated by various regulatory bodies globally like FDA in USA and EMA in Europe to ensure safety and efficacy of new therapies. Favourable regulations and support from governments promote the growth of this sector.
Economic: High costs associated with R&D and manufacturing of cell therapies act as a restraint initially. However, the increasing prevalence of chronic diseases boost the economic incentives for industry players to invest in this sector to tap the market potential.
Social: Increasing awareness among people regarding potential benefits of cell therapies in treating various life-threatening conditions is driving their acceptance. There is a strong social demand for advanced treatment options.
Technological: Significant advancements are being made in areas of cell manipulation, gene editing, scaffolds/carrier material which is supporting development of more potent and targeted cell therapy products. Automation and digital technologies help in improving process efficiencies.
The Global Cell Therapy Market Size is projected to grow at a CAGR of 3.4% during the forecast period of 2023 to 2030. The global cell therapy market is estimated to be valued at US$ 16.4 billion in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030.
Regional analysis indicates that North America is currently the dominant region for cell therapy market owing to presence of major players and rapid adoption of advanced treatment options. North America is projected to retain its leading position and grow at a CAGR of around 4% during the forecast period.
Key players operating in the cell therapy market are Novartis AG, Gilead Sciences, Celgene Corporation, Bluebird Bio, Vericel Corporation, U.S. Stem Cell Inc. and Fibrocell Science Inc. Key players are investing heavily in R&D to develop more effective and scalable manufacturing processes and make cell therapies available for wide range of clinical indications. Partnerships and co-development activities between companies are increasingly emerging to bring new therapy candidates into the clinics at a faster pace.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it